EyePoint, Inc. is facing a significant legal challenge with the filing of a securities class action lawsuit. The complaint, filed on November 17, 2026, in the U.S. District Court for the Eastern District of New York, alleges that the company and its executives made materially false and misleading statements regarding its lead product candidate, DURAVYU. The lawsuit could have serious implications for EyePoint's reputation and operations.
The lawsuit, titled Marco Kälin v. EyePoint, Inc., et al., claims violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as Rule 10b-5. It is brought by Marco Kälin on behalf of a putative class of investors who purchased or acquired EyePoint securities between May 27, 2025, and August 14, 2026. The complaint seeks unspecified damages, attorneys' fees, expert fees, and other costs.
EyePoint, Inc., incorporated in Delaware, operates in the laboratory analytical instruments sector, specifically focusing on developing innovative therapies for eye diseases. The company trades under the ticker symbol EYPT on the Nasdaq exchange. Recent filings indicate that EyePoint is a smaller reporting company, which may affect its legal and financial strategies.
According to the filing, EyePoint believes the allegations in the lawsuit lack merit and intends to defend itself vigorously against these claims. The outcome of this lawsuit could not only affect EyePoint's financial standing but also set a precedent for other companies in the laboratory analytical instruments industry, which may face similar scrutiny regarding their product representations.
The filing does not specify what happens next in the legal process, leaving stakeholders and investors to await further developments in this case.
Read Next
Clark Kyle Sells 15,000 Shares of Beta Technologies Stock
Ronald R. Taylor resigns as director of ResMed Inc.
Afsari Nasym acquires 68,235 shares of Onterris, Inc.
Onterris, Inc. Chief Strategy Officer Acquires Shares
StubHub Holdings' Mark Streams Sells 76,891 Shares
Francesca M. Edwardson Transfers 25,000 Shares to Trust




